Dashboard
1
Company has very low debt and has enough cash to service the debt requirements
2
Poor long term growth as Net Sales has grown by an annual rate of 5.47% over the last 5 years
3
Negative results in Jun 25
4
With ROE of 4.82%, it has a very attractive valuation with a 0.72 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 9,209 Million (Micro Cap)
15.00
NA
0.02%
0.02
4.52%
0.77
Revenue and Profits:
Net Sales:
3,343 Million
(Quarterly Results - Jun 2025)
Net Profit:
163 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.39%
0%
-2.39%
6 Months
2.37%
0%
2.37%
1 Year
4.1%
0%
4.1%
2 Years
0.7%
0%
0.7%
3 Years
13.5%
0%
13.5%
4 Years
14.29%
0%
14.29%
5 Years
14.29%
0%
14.29%
Morishita Jintan Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.47%
EBIT Growth (5y)
6.60%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.96
Tax Ratio
29.15%
Dividend Payout Ratio
41.11%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.03%
ROE (avg)
3.91%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
0.72
EV to EBIT
12.99
EV to EBITDA
6.75
EV to Capital Employed
0.70
EV to Sales
0.64
PEG Ratio
NA
Dividend Yield
0.02%
ROCE (Latest)
5.40%
ROE (Latest)
4.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
3,343.00
3,170.00
5.46%
Operating Profit (PBDIT) excl Other Income
344.00
469.00
-26.65%
Interest
5.00
5.00
Exceptional Items
0.00
-96.00
100.00%
Consolidate Net Profit
163.00
197.00
-17.26%
Operating Profit Margin (Excl OI)
58.30%
100.30%
-4.20%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 5.46% vs -1.31% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -17.26% vs 17.26% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
12,766.00
12,406.00
2.90%
Operating Profit (PBDIT) excl Other Income
1,382.00
1,293.00
6.88%
Interest
8.00
2.00
300.00%
Exceptional Items
-96.00
5.00
-2,020.00%
Consolidate Net Profit
547.00
697.00
-21.52%
Operating Profit Margin (Excl OI)
63.00%
57.80%
0.52%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 2.90% vs 9.22% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -21.52% vs 41.96% in Mar 2024
About Morishita Jintan Co., Ltd. 
Morishita Jintan Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






